Bluejay Diagnostics, Inc. (BJDX)

0.5470 +0.0092 (+1.71%) At close: 04:00PM EDT

Bluejay Diagnostics, Inc.

360 Massachusetts Avenue
Suite 203
Acton, MA 01720
United States
844 327 7078
https://bluejaydx.com

Sector(s): Healthcare
Industry: Medical Devices
Full-time employees: 10

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Indranil Dey	Principal Financial, Accounting & Executive Officer, President, CEO and Director	292.15k	N/A	1964
Dr. Jason Cook	Chief Technology Officer	240.29k	N/A	1983
Mr. Les DeLuca	Vice President of Operations	N/A	N/A	N/A
Eryn Graham	Marketing Manager	N/A	N/A	N/A
Mr. Kevin Vance	Chief Commercial Officer	N/A	N/A	1958
Mark W. Feinberg	Chief Medical Advisor	N/A	N/A	N/A
Dr. Mark W. Feinberg M.D.	Chief Medical Advisor	N/A	N/A	N/A
Ryan McSeveney	Corporate Controller	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Bluejay Diagnostics, Inc. operates as a medical diagnostics company. The company offers Symphony platform, a technology platform comprising Symphony analyzer that orchestrates whole blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. It also provides ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, the company develops Symphony IL-6 test for the monitoring of disease progression in critical care settings. Further, it develops cardiac biomarkers, such as hsTNT and NT pro-BNP, as well as other tests using the Symphony platform. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.

Corporate governance

Bluejay Diagnostics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.